Africa: Twice-Yearly Lenacapavir Continues to Show Strong HIV Prevention Results
Twice-yearly injectable lenacapavir has continued to demonstrate exceptional protection against HIV infection. Twice-yearly injectable lenacapavir continued to provide strong protection against HIV in two landmark clinical trials, with updated data showing almost no new infections, high adherence and no new safety concerns. Researchers said updated findings from the PURPOSE-1 and PURPOSE-2 studies showed the long-acting…
